LU
LUNG.US Pulmonx Corp
- Market cap
- USD 122M
- P/E
- -
- P/B
- 3.63x
- ROE
- -125.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LUNG.US undervalued?
Graham numberThe Graham number of Pulmonx Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pulmonx Corp fundamental analysis
No fundamental analysis for Pulmonx Corp yet.
Pulmonx Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pulmonx Corp
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative …
Full company profilePulmonx Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pulmonx Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 8.80K | 0.00 | 20.0M | 32.6M | 32.7M | 48.4M | 53.7M | 68.7M | 83.8M | 90.5M | 88.2M |
| Gross Profit | -1.39K | 0.00 | 12.3M | 22.4M | 21.2M | 35.6M | 39.9M | 50.8M | 62.0M | 67.1M | 68.2M |
| Operating Income | -2.51M | -5.25M | -15.1M | -17.8M | -32.3M | -47.3M | -58.6M | -61.9M | -57.7M | -53.7M | -39.3M |
| EBITDA | - | - | -15.7M | -17.7M | -28.4M | -46.6M | -56.0M | -55.5M | -50.9M | -49.2M | -36.8M |
| Net Income | -2.78M | -5.37M | -18.5M | -20.7M | -32.2M | -48.7M | -58.9M | -60.8M | -56.4M | -54.0M | -42.8M |
| EPS | - | - | -0.89 | -0.58 | -0.90 | -1.35 | -1.59 | -1.60 | -1.44 | -1.33 | -0.99 |
| Balance Sheet | |||||||||||
| Total Assets | 578K | 1.47M | 15.0M | 53.5M | 264M | 235M | 194M | 178M | 163M | 129M | 110M |
| Total Liabilities | 3.41M | 1.53M | 182M | 241M | 37.6M | 41.9M | 39.7M | 59.5M | 77.0M | 75.2M | 76.0M |
| Shareholders' Equity | -2.84M | -63.2K | -167M | -187M | 226M | 193M | 154M | 118M | 85.8M | 54.1M | 34.2M |
| Cash & Short-term Investments | 28.9K | 637K | 4.12M | 28.3M | 232M | 180M | 141M | 117M | 101M | 70.0M | 52.7M |
| Total Debt | - | - | 33.6M | 227M | 27.2M | 26.5M | 24.4M | 41.4M | 56.5M | 56.4M | 56.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.03M | -4.64M | -18.4M | -20.8M | -30.6M | -41.4M | -45.1M | -37.6M | -31.5M | -32.4M | -24.7M |
| Capital Expenditure | 27.2K | 27.2K | 316K | 720K | 911K | 3.67M | 1.32M | 807K | 1.45M | 452K | 24.0K |
| Free Cash Flow | - | - | -18.7M | -21.5M | -31.5M | -45.1M | -46.5M | -38.4M | -33.0M | -32.9M | -24.7M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -14.3% | -25.2% | -38.3% | -51.4% | -65.7% | -99.8% | -125.3% |
| ROA | -480.2% | -366.5% | -123.1% | -38.7% | -12.2% | -20.7% | -30.4% | -34.2% | -34.6% | -41.8% | -38.9% |
| Net Profit Margin | -31,539.3% | - | -92.4% | -63.5% | -98.5% | -100.5% | -109.8% | -88.6% | -67.3% | -59.7% | -48.5% |
| Debt to Equity | - | - | - | - | 0.12x | 0.14x | 0.16x | 0.35x | 0.66x | 1.04x | 1.65x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pulmonx Corp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 21.4M | 0.56 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 21.0K | 0.00 | - |
| 2019 | USD 46.2M | 1.30 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Pulmonx Corp
- Insiders 4.66%
- Institutions 61.86%
- Public & others 33.48%
- Shares outstanding 43.6M
- Free float 38.2M
Top funds holding LUNG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| PRIMECAP Odyssey Aggressive Growth | 3.48M | 8.00% | -3.33% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.15M | 2.65% | 0.00% | Sep 2026 |
| Vanguard US Opportunities Ins USD Acc | 490K | 1.13% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 191K | 0.44% | +23.55% | Sep 2026 |
| iShares Micro-Cap ETF | 125K | 0.29% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 112K | 0.26% | +296.24% | Aug 2026 |
| Fidelity Total Market Index | 73.8K | 0.17% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 62.0K | 0.14% | 0.00% | Sep 2026 |
| Abante Quant Value FI | 60.7K | 0.14% | 0.00% | Aug 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 34.3K | 0.08% | 0.00% | Oct 2026 |
| Mackenzie GQE US Small Cap F8 | 29.8K | 0.07% | 0.00% | Aug 2026 |
| Pacific Select Large-Cap Growth I | 23.3K | 0.05% | 0.00% | Oct 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 22.3K | 0.05% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 19.1K | 0.04% | 0.00% | Sep 2026 |
| Strategic Advisers U.S. Total Stock | 14.4K | 0.03% | +2.40% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 13.6K | 0.03% | 0.00% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 13.4K | 0.03% | 0.00% | Oct 2026 |
| DFA US Micro Cap I | 12.4K | 0.03% | +91.91% | Sep 2026 |
Top institutions holding LUNG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| PRIMECAP Management Company | 4.41M | 10.12% | -4.42% | Sep 2026 |
| Morgan Stanley - Brokerage Accounts | 2.92M | 6.71% | -26.81% | Jun 2026 |
| Soleus Capital Management, L.P. | 2.79M | 6.40% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.63M | 3.74% | -0.25% | Jun 2026 |
| ExodusPoint Capital Management, LP | 1.22M | 2.81% | -37.05% | Jun 2026 |
| Almitas Capital LLC | 1.06M | 2.44% | 0.00% | Jun 2026 |
| BlackRock Inc | 882K | 2.03% | -66.84% | Jun 2026 |
| Stonepine Capital Management Llc | 815K | 1.87% | +6.14% | Jun 2026 |
| Jane Street Group LLC | 758K | 1.74% | +468.94% | Jun 2026 |
| BRAIDWELL LP | 753K | 1.73% | 0.00% | Jun 2026 |
| AQR Capital Management LLC | 745K | 1.71% | +108.34% | Jun 2026 |
| Parkman Healthcare Partners LLC | 647K | 1.48% | -14.43% | Jun 2026 |
| Renaissance Technologies Corp | 530K | 1.22% | +24.75% | Sep 2026 |
| Acadian Asset Management LLC | 523K | 1.20% | +134.38% | Sep 2026 |
| Geode Capital Management, LLC | 453K | 1.04% | -52.07% | Jun 2026 |
| ADAR1 Capital Management LLC | 404K | 0.93% | +8.01% | Jun 2026 |
| Deutsche Bank AG | 402K | 0.92% | -65.43% | Jun 2026 |
| D. E. Shaw & Co LP | 328K | 0.75% | -2.25% | Jun 2026 |
| Jefferies Financial Group Inc | 285K | 0.65% | 0.00% | Jun 2026 |
| CFM WEALTH PARTNERS LLC | 264K | 0.61% | 0.00% | Jun 2026 |
Pulmonx Corp company profile
- Company name
- Pulmonx Corp
- Ticker
- LUNG.US
- Exchange
- USA Stocks
- Listed since
- Oct 1, 2020
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 296
- Fiscal year end
- December
- Address
- 700 Chesapeake Drive, Redwood City, CA, United States, 94063
- Phone
- 650 364 0400
- Website
- pulmonx.com
About Pulmonx Corp
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Pulmonx Corp management
9- Mr. Glendon E. FrenchCEO, President & Director · born 1962
- Dr. Derrick Sung Ph.D.CFO & COO · born 1973
- Mr. David A. Lehman J.D.General Counsel & Secretary · born 1961
- Mr. Srikanth RadhakrishnanChief Science & Technology Officer · born 1973
- Ms. Marcee M. MaroneyVice President of Marketing · born 1970
- Mr. Jérôme ErathSenior VP & GM of International
- Mr. Geoffrey Beran RoseChief Commercial Officer · born 1974
- Dr. Narinder S. Shargill Ph.D.Senior Vice President of Global Medical & Clinical Affairs · born 1955
- Mr. John B. McKuneVP of Finance & Corporate Controller · born 1976